ES2180523T3 - Composicion que comprende insulina nph (insulina neutra protamina de hagedorn). - Google Patents

Composicion que comprende insulina nph (insulina neutra protamina de hagedorn).

Info

Publication number
ES2180523T3
ES2180523T3 ES01106315T ES01106315T ES2180523T3 ES 2180523 T3 ES2180523 T3 ES 2180523T3 ES 01106315 T ES01106315 T ES 01106315T ES 01106315 T ES01106315 T ES 01106315T ES 2180523 T3 ES2180523 T3 ES 2180523T3
Authority
ES
Spain
Prior art keywords
insulin
hagedorn
neutral
composition including
nph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01106315T
Other languages
English (en)
Inventor
Ross G Clark
James Q Oeswein
Douglas A Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2180523T3 publication Critical patent/ES2180523T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición que comprende insulina NPH (insulina neutra protamina de Hagedorn) en un tampón de sal de ácido acético sin la presencia de IGF-I.
ES01106315T 1996-08-13 1997-07-31 Composicion que comprende insulina nph (insulina neutra protamina de hagedorn). Expired - Lifetime ES2180523T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/696,314 US5783556A (en) 1996-08-13 1996-08-13 Formulated insulin-containing composition

Publications (1)

Publication Number Publication Date
ES2180523T3 true ES2180523T3 (es) 2003-02-16

Family

ID=24796556

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01106315T Expired - Lifetime ES2180523T3 (es) 1996-08-13 1997-07-31 Composicion que comprende insulina nph (insulina neutra protamina de hagedorn).
ES97935259T Expired - Lifetime ES2162321T3 (es) 1996-08-13 1997-07-31 Composicion que comprende insulina y factor de crecimiento-i similar a la insulina (igf-i).

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES97935259T Expired - Lifetime ES2162321T3 (es) 1996-08-13 1997-07-31 Composicion que comprende insulina y factor de crecimiento-i similar a la insulina (igf-i).

Country Status (16)

Country Link
US (1) US5783556A (es)
EP (2) EP0918536B1 (es)
JP (1) JP4187075B2 (es)
AR (1) AR009066A1 (es)
AT (2) ATE205722T1 (es)
AU (1) AU731745B2 (es)
CA (1) CA2261799C (es)
DE (2) DE69714796T2 (es)
DK (2) DK0918536T3 (es)
ES (2) ES2180523T3 (es)
HK (1) HK1042229B (es)
IL (1) IL128128A (es)
PT (2) PT1114644E (es)
SI (1) SI1114644T1 (es)
WO (1) WO1998006423A1 (es)
ZA (1) ZA976598B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
CN1250379A (zh) * 1997-01-23 2000-04-12 住友制药株式会社 糖尿病治疗剂
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
EP2823812A1 (en) 1998-02-02 2015-01-14 Trustees Of Tufts College Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
CA2369451C (en) * 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
CA2369839A1 (en) * 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
EP2280004B1 (en) 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
SE0101980D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
FR2826278B1 (fr) * 2001-06-20 2005-03-25 Lipha Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
EP2316470A3 (en) * 2001-11-26 2011-08-24 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
EP1487471A4 (en) * 2001-11-26 2010-03-10 Tufts College METHOD FOR TREATING AUTOIMMUNE DISEASES AND ASSOCIATED REAGENTS
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CA2512052C (en) 2002-12-31 2016-06-21 Altus Pharmaceuticals Inc. Human growth hormone crystals and methods for preparing them
EA200501422A1 (ru) * 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
PL2319500T3 (pl) * 2004-03-12 2013-05-31 Biodel Inc Szybko działające kompozycje do dostarczania leku
US8989833B2 (en) 2004-07-13 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
US20090060861A1 (en) * 2005-05-25 2009-03-05 Novo Nordisk A/S Stabilized Polypeptide Formulations
WO2006125763A1 (en) * 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
US20090147006A1 (en) * 2007-12-07 2009-06-11 Roche Diagnostics Operations, Inc. Method and system for event based data comparison
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
SG10201507036TA (en) 2008-06-13 2015-10-29 Mannkind Corp A dry powder inhaler and system for drug delivery
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2010089706A1 (en) 2009-02-04 2010-08-12 Ecole Polytechnique Federale De Lausanne (Epfl) Use of igf-1 and nt-3 in the treatment of x-linked adrenoleukodystrophy
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
MX2011009512A (es) 2009-03-11 2011-11-29 Mannkind Corp Aparato, sistema y metodo para medir la resistencia de un inhalador.
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
CN102724913A (zh) 2009-09-30 2012-10-10 德克斯康公司 经皮分析物传感器
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
HK1200318A1 (en) 2011-10-24 2015-08-07 曼金德公司 Methods and compositions for treating pain
EP2872205B1 (en) 2012-07-12 2017-02-08 MannKind Corporation Dry powder drug delivery systems
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
BR112015013223A2 (pt) * 2012-12-26 2017-07-11 Wockhardt Ltd composição farmacêutica
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
EP3091965A1 (en) * 2014-01-09 2016-11-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
ES3005966T3 (en) * 2020-10-19 2025-03-17 Oak Hill Bio Ltd Compositions suitable for use in neonates
DE102021122096A1 (de) * 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486216T2 (de) * 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
US5091173A (en) * 1989-06-29 1992-02-25 The University Of Dundee Hair growth composition
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
JPH0818999B2 (ja) * 1990-01-05 1996-02-28 藤沢薬品工業株式会社 インシュリン様成長因子ｉの乾燥製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
CA2109794A1 (en) * 1991-05-24 1992-11-26 Timothy J. Rink Amylin and possibly insulin containing composition for the treatment of anorexia and related states
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
JPH0543453A (ja) * 1991-08-20 1993-02-23 Sumitomo Pharmaceut Co Ltd 創傷治癒促進用局所用徐放性製剤
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
WO1993010806A1 (en) * 1991-11-25 1993-06-10 Institute Of Molecular Biology, Inc. Medicament for promoting growth of mammalian nerve
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
WO1994000010A1 (en) * 1992-06-24 1994-01-06 Wilson Walter Rd Organic pesticide
ES2174852T3 (es) * 1992-08-26 2002-11-16 Celtrix Pharma Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
WO1994016722A1 (en) * 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
KR960700069A (ko) * 1993-01-29 1996-01-19 다니엘 바프네크 상처 치료용 조성물(wound healing composition)
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
AUPM678294A0 (en) * 1994-07-13 1994-08-04 Gropep Pty Ltd Use of insulin-like growth factor in combination with insulin
ES2316161T3 (es) * 1998-01-09 2009-04-01 Amylin Pharmaceuticals, Inc. Formulaciones para peptidos agonistas de amilina con insulina.
DE69920767T2 (de) * 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
CA2369451C (en) * 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
CA2369839A1 (en) * 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes

Also Published As

Publication number Publication date
JP2000516229A (ja) 2000-12-05
ZA976598B (en) 1999-02-17
DE69714796T2 (de) 2003-04-03
EP1114644A1 (en) 2001-07-11
IL128128A (en) 2007-06-17
US5783556A (en) 1998-07-21
EP0918536B1 (en) 2001-09-19
DK0918536T3 (da) 2001-12-03
HK1042229B (en) 2003-08-15
EP1114644B1 (en) 2002-08-14
AU3824397A (en) 1998-03-06
ES2162321T3 (es) 2001-12-16
DE69706872D1 (de) 2001-10-25
CA2261799C (en) 2009-09-08
ATE205722T1 (de) 2001-10-15
AU731745B2 (en) 2001-04-05
DE69706872T2 (de) 2002-04-25
IL128128A0 (en) 1999-11-30
ATE222120T1 (de) 2002-08-15
CA2261799A1 (en) 1998-02-19
DK1114644T3 (da) 2002-11-04
JP4187075B2 (ja) 2008-11-26
PT918536E (pt) 2002-03-28
AR009066A1 (es) 2000-03-08
HK1042229A1 (en) 2002-08-09
DE69714796D1 (de) 2002-09-19
PT1114644E (pt) 2002-12-31
SI1114644T1 (en) 2002-12-31
EP0918536A1 (en) 1999-06-02
WO1998006423A1 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
DE69714796D1 (de) Zusammensetzung die NPH-Insulin (Neutral-protamin Hagedorn Insulin) enthält
AU7261994A (en) Hydrazino-type radionuclide chelators having an n3s configuration
DE59306544D1 (de) Verwendungen von alpha-Hydroxyfettsäuren
EP1302848A3 (en) A microprocessor having a multiply operation
AU7528894A (en) Hydrazino-type n2s2 chelators
DE69500043D1 (de) Schleifmittelzusammensetzung mit Tensidsystem
AU8458382A (en) B. thuringiensis crystal protein in e. coli
DE69004242D1 (de) Laktoferrinhydrolysat zur Verwendung als antibakterielles Mittel.
ZA944283B (en) Gps-aided dead reckoning navigation
AU4298596A (en) Protracted glp-1 compositions
AU1094892A (en) Improved activation of recombinant proteins
AU2724492A (en) Antibodies in immunosuppression
AU1378395A (en) Metal chelators
FI853220A7 (fi) Aminoalkoksibentsopyranonit antipsykoottisina ja anksiolyyttisinä aineina.
AU7949391A (en) Kit for the specific assay of angiotensin ii
FI854678A7 (fi) Motordriven truck.
ES2119161T3 (es) Soluciones de dialisis peritoneal mejoradas que incluyen polipeptidos.
FR2705430B1 (fr) Connecteur rapide.
EP0806821A3 (en) Polirazed superfluorescent fiber sources
AU555226B2 (en) Cloning vehicles for polypeptide expression in microbial hosts
BR9402493A (pt) Composição de micro-emulsão ácida
EP0825257A3 (en) Protein involved in regenerating luciferin
DE3862066D1 (de) Anschlagpufferanordnung fuer schwenkbare karosserieteile.
ATE294189T1 (de) Kristallisation von proteinen
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent